| abstract |
Kallikrein 5 constitutes a novel biomarker for diagnosis, treatment and monitoring of breast and ovarian cancer. A method is provided for diagnosing and monitoring breast or ovarian cancer or a predisposition to breast or ovarian cancer, in a subject comprising detecting kallikrein 5 in a sample from the subject. Imaging methods, screening methods for test agents for inhibiting breast or ovarian cancer, and therapeutic applications based on kallikrein 5 are also described. |